Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for period ended September 30, 2026 announced November 3, 2026.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced November 3, 2026
- Investors should review Exhibit 99.1 for financial results and management commentary
Item 7.01 · Regulation FD Disclosure
- Amneal scheduled a November 3, 2026 conference call and webcast to discuss results
- Investor presentation and webcast available through Amneal’s Investor Relations website
- Results discussion provides investors management commentary beyond the financial release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $863M, up 10%, led by Affordable Medicines growth of 19% and Specialty growth of 20%
- Adjusted EBITDA $207M, up 30%, while GAAP net loss reached $22M due to acquisition costs and higher taxes
- Adjusted diluted EPS $0.26, up 53%, contrasting with GAAP diluted loss per share of $(0.06)
- 2026 guidance raised: revenue $3.15B-$3.25B, adjusted EBITDA $800M-$815M, adjusted EPS $1.04-$1.08
- Cash-flow outlook reduced: operating cash flow $325M-$375M, with higher inventory and Kashiv integration costs pressuring liquidity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.